Communiqués Therapeutic Solutions International, Inc. Other OTC

Actions

TSOI

US8833781011

Recherche biotechnologique et médicale

Communiqués

13/07/23	Therapeutic Solutions International Files for Orphan Drug Designation Use of JadiCell Adult Stem Cells for Treatment of Frontotemporal Dementia	AQ
29/03/23	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	AQ
27/03/23	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. : Other Events (form 8-K)	AQ
21/02/23	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. : Entry into a Material Definitive Agreement, Other Events (form 8-K)	AQ
10/02/23	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. : Other Events (form 8-K)	AQ
06/12/22	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
29/11/22	Therapeutic Solutions International Granted Broad Patent on Treatment of Neurodegenerative Conditions	AQ
17/11/22	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
25/10/22	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. : Other Events (form 8-K)	AQ
20/09/22	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. : Entry into a Material Definitive Agreement (form 8-K)	AQ
20/09/22	Therapeutic Solutions International Spin-Off Company Campbell Neurosciences Announces Successful Preclinical Studies of CampbellCell for Treatment of Bipolar Disorder	AQ
19/08/22	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
15/08/22	Therapeutic Solutions International Reports Superior Efficacy of ApoptoCyte on Chronic Obstructive Pulmonary Disease Model Compared to Conventional Stem Cell Approaches	AQ
23/05/22	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
11/05/22	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. : Entry into a Material Definitive Agreement (form 8-K)	AQ
02/05/22	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. : Entry into a Material Definitive Agreement (form 8-K)	AQ
31/03/22	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K)	AQ
30/03/22	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Entry into a Material Definitive Agreement (form 8-K/A)	AQ
25/03/22	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. : Entry into a Material Definitive Agreement (form 8-K)	AQ
04/03/22	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. : Entry into a Material Definitive Agreement (form 8-K)	AQ
22/11/21	THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
11/10/21	Therapeutic Solutions International : Announces Initiation of JadiCell™ Manufacturing Program to Address Upcoming FDA Phase III Trial and Emergency Use Requests	PR
04/10/21	Therapeutic Solutions International : Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production	PR
27/09/21	Therapeutic Solutions International : Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing	PR
22/09/21	Therapeutic Solutions International : Discovers and Files Patent on Novel Cellular Therapy Combination for Augmentation of Lung Repair in COVID-19 Model	PR